

COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Balance Sheet as at 31st March 2026

(All amounts in Lakhs Rupees except for share data or as otherwise stated)

Particulars		Notes	As at March 31, 2026	As at March 31, 2025
I.	ASSETS			
(1)	Non Current Assets			
(a)	Property, plant and equipment	2.01	15,352.90	60.29
(b)	Capital work in progress	2.02	58.95	13,477.92
(c)	Right-of-use asset	2.03	75.74	77.16
(d)	Other Intangible assets	2.04	1.05	-
(e)	Financial assets			
-	Other financial assets	2.05	66.32	34.82
(f)	Other non current assets	2.06	345.99	1,139.43
			15,900.95	14,789.62
(2)	Current Assets			
(a)	Inventories	2.07	1,953.78	30.17
(b)	Financial assets:			
(i)	Trade receivables	2.08	2,917.49	-
(ii)	Cash & cash equivalents	2.09	384.34	41.52
(iii)	Bank balances other than above (ii)	2.10	1,050.64	914.33
(iv)	Other financial assets	2.11	-	-
(c)	Current Tax Assets (Net)	2.12	326.16	-
(d)	Other Current assets	2.13	1,706.54	1,969.01
			8,338.94	2,955.03
	Total Assets		24,239.90	17,744.66
II.	EQUITY and LIABILITIES			
(1)	Equity			
(a)	Equity share capital	2.14	2,810.00	2,810.00
(b)	Other equity	2.15	1,358.15	(24.64)
	Total Equity		4,168.15	2,785.36
(2)	Non Current Liabilities			
(a)	Financial liabilities:			
(i)	Borrowings	2.16	8,683.27	10,524.35
(ii)	Lease Liability	2.03	8.47	8.49
(b)	Deferred tax liabilities (Net)	2.17	370.32	-
			9,062.07	10,532.83
(3)	Current Liabilities			
(a)	Financial liabilities:			
(i)	Borrowings	2.18	8,771.61	3,762.84
(ii)	Lease Liability	2.03	0.79	0.79
(iii)	Trade payables	2.19		
	(A) total outstanding dues of micro enterprises and small enterprises		0.56	2.96
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises		2,091.74	635.13
(iv)	Other financial liabilities	2.20	122.58	12.11
(a)	Provisions	2.21	7.02	-
(b)	Other current liabilities	2.22	15.38	4.76
(c)	Current Tax Liabilities	2.23	-	7.88
			11,009.68	4,426.47
	Total Equity and Liabilities		24,239.90	17,744.66
	Summary of significant accounting policies The accompanying notes are an integral part of the financial statements	1		

As per the report of even date

For, and on behalf of the Board

for, Brahmayya & Co
Chartered Accountants
Firm Reg No. 000513S

Partner
C.V.Ramana Rao
Partner
Membership No. 018545
Place: Visakhapatnam
Date: 30.05.2026



G.V.V.Satyanarayana
Director (Finance) & CFO
(DIN: 0000187006)

T.Valsaraj
Director & Chairman
(DIN: 0000057558)

Swaroop Meruva
Company Secretary

COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Statement of Profit and Loss for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

Particulars	Notes	For the year ended 31st March, 2026	For the year ended 31st March, 2025
I. INCOME			
Revenue from Operations	2.24	24,082.42	-
Other Income	2.25	392.31	53.98
Total Revenue (I)		24,474.73	53.98
II. EXPENSES			
Cost of Materials Consumed	2.26	21,090.50	-
(Increase)/Decrease in Inventories of Finished Goods	2.27	(782.63)	-
Operating expenses	2.28	661.42	0.98
Employee Benefits Expenses	2.29	238.52	-
Finance charges	2.30	738.72	0.24
Depreciation and Amortisation	2.31	313.14	5.64
Other Expenses	2.32	465.45	60.79
Total Expenses (II)		22,725.12	67.65
III. Profit Before Tax (I-II)		1,749.61	(13.67)
IV. Tax Expense			
Current tax	2.33	-	13.14
Direct taxes paid for earlier years		(3.50)	-
Deferred tax		370.32	-
		366.82	13.14
V. Profit for the year (III -IV)		1,382.79	(26.81)
VI. OTHER COMPREHENSIVE INCOME (OCI)			
(i) Items will not be reclassified to profit or loss in subsequent periods:		-	-
(ii) Items that will be reclassified to profit or loss		-	-
Total comprehensive income for the year, net of tax		1,382.79	(26.81)
Earnings Per Equity Share	2.34		
Basic (Rs.)		4.92	(0.10)
Diluted (Rs.)		4.92	(0.10)
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements			

As per the report of even date

for, and on behalf of the Board

for, Brahmayya & Co
Chartered Accountants
Firm Reg No. 000513S

C.V. Ramana Rao
Partner
C.V. Ramana Rao
Partner
Membership No. 018545
Place: Visakhapatnam
Date: 30.05.2026



G.V.V. Satyanarayana
Director (Finance) & CFO
(DIN: 0000187006)

T. Valsaraj
Director & Chairman
(DIN: 0000057558)

Swaroop Meruva
Swaroop Meruva
Company Secretary

COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Statement of Cash Flows for period ended March 31, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

Particulars		For the period ended March 31, 2025	For the period ended March 31, 2025
(A)	CASH FLOWS FROM OPERATING ACTIVITIES		
	Profit before tax	1,749.61	(13.67)
	Adjustments for :		
	Depreciation of property, plant and equipment	311.92	5.64
	Amortisation of ROU Asset	1.22	2.10
	Interest Income	(54.93)	(53.96)
	Interest Expense on Delayed payment to MSME Suppliers	0.32	0.17
	Interest Expense	692.47	0.08
	Operating profit before working capital changes	2,700.60	(59.65)
	Movement in working capital:		
	(Increase)/Decrease in Inventories	(1,923.61)	(30.17)
	(Increase)/Decrease in Trade Receivables and Other Receivables	(2,951.34)	(40.76)
	Increase/(Decrease) in Trade payables and Other payables	1,578.60	635.90
	Cash generated from operations	(595.75)	505.32
	Income tax paid	(326.16)	(5.26)
	Net cash flows from operating activities (A)	(921.91)	500.06
(B)	CASH FLOWS FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment, including intangible assets, capital work in progress and capital advances	(14,547.32)	(43.66)
	Increase in Capital Work in Progress	13,418.97	(5,535.28)
	Proceed from transfer of right in Lease property	(0.79)	(0.76)
	Interest received	54.93	53.96
	Net cash flows used in investing activities (B)	(1,074.20)	(5,525.73)
(C)	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from issue of equity shares to holding company	-	10.00
	Proceeds from Securities Premium	-	-
	Proceeds from borrowings	3,167.69	4,579.83
	Repayments of borrowings	-	-
	Interest paid	(692.47)	(0.08)
	Net cash flows from financing activities (C)	2,475.23	4,589.75
	Net decrease in cash and cash equivalents (A+B+C)	479.12	(435.92)
	Cash and cash equivalents at the beginning of the year	955.85	1,391.77
	Cash and cash equivalents at the year end	1,434.97	955.85
	Components of cash and cash equivalents:		
	Cash on hand	0.09	0.28
	Balances with banks		
	-On current accounts	384.25	41.23
	On dividend accounts		
	-On deposit accounts	1,050.64	914.33
	Total cash and cash Equivalents	1,434.97	955.85

The accompanying notes are an integral part of the standalone financial statements.

As per the report of even date

for,
Chartered Accountants
Firm Reg No. 000513S

Partner
C.V.Ramana Rao
Partner
Membership No. 018545
Place: Visakhapatnam
Date: 30.05.2026



For, and on behalf of the Board

G.V.V.Satyanarayana
Director (Finance) & CFO
(DIN: 0000187006)

T.Valsaraj
Director & Chairman
(DIN: 0000057558)

Swaroop Meruva
Company Secretary

COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Statement of Changes in Equity for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

a. Equity Share Capital

As at 31.03.2026

Balance at 01.04.2025	Changes in Equity Share Capital due to prior period errors	Restated balance as at 01.04.2025	Changes in equity share capital during the current year	Balance as at 31.03.2026
2,810.00	-	2,810.00	-	2,810.00

As at 31.03.2025

Balance at 01.04.2024	Changes in Equity Share Capital due to prior period errors	Restated balance as at 01.04.2024	Changes in equity share capital during the current year	Balance as at 31.03.2025
2,800.00	-	2,800.00	10.00	2,810.00

Other Equity (as at 31st March,2026)

	Reserves and Surplus				Items of Other Comprehensive Income		Foreign Currency Translation Reserve	Total Other Equity
	Capital Reserve	Securities Premium	General Reserve	Retained Earnings	Equity Instruments through Other Comprehensive Income	Remeasurement gains/(losses) on the defined benefit obligations		
Balance at 01.04.2025	-	-	-	(24.64)	-	-	-	(24.64)
Changes in accounting policy/prior period errors	-	-	-	-	-	-	-	-
Restated balance at 01.04.2025	-	-	-	(24.64)	-	-	-	(24.64)
Total Comprehensive Income for the year	-	-	-	1,382.79	-	-	-	1,382.79
Dividend	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-
Balance at 31.03.2026	-	-	-	1,358.15	-	-	-	1,358.15

b. Other Equity (as at 31st March,2025)

	Reserves and Surplus				Items of Other Comprehensive Income		Foreign Currency Translation Reserve	Total Other Equity
	Capital Reserve	Securities Premium	General Reserve	Retained Earnings	Equity Instruments through Other Comprehensive Income	Remeasurement gains/(losses) on the defined		
Balance at 01.04.2024	-	-	-	2.17	-	-	-	2.17
Changes in accounting policy/prior period errors	-	-	-	-	-	-	-	-
Restated balance at 01.04.2024	-	-	-	2.17	-	-	-	2.17
Total Comprehensive Income for the year	-	-	-	(26.81)	-	-	-	(26.81)
Foreign Currency Translation Reserve	-	-	-	-	-	-	-	-
Dividend	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-
Balance at 31.03.2025	-	-	-	(24.64)	-	-	-	(24.64)

As per the report of even date

for, Brahmayya & Co
Chartered Accountants
Firm Reg No. 0005135

Partner
C.V.Ramana Rao
Partner
Membership No. 018545
Place: Visakhapatnam
Date: 30.05.2026



For, and on behalf of the Board

G.V.V.Satyanarayana
Director (Finance & CFO)
(DIN: 0000187006)

Swaropa Meruva
Company Secretary

T.Valsaraj
Director & Chairman
(DIN: 0000057558)

COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March ,2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.01 Property, Plant and Equipment as at 31st March,2026

Particulars	Gross Block				Depreciation				Net Block	
	Balance as at 01.04.2025	Additions	Disposals	Balance as at 31.03.2026	Upto 01.04.2025	For the period	On disposals	Total upto 31.03.2026	Balance as at 31.03.2026	Balance as at 31.03.2025
Buildings	-	4,654.06	-	4,654.06	-	74.60	-	74.60	4,579.46	-
Plant & Machinery	-	10,687.64	-	10,687.64	-	215.95	-	215.95	10,471.69	-
Furniture & Fixtures	-	8.38	-	8.38	-	0.49	-	0.49	7.90	-
Computers	2.68	9.21	-	11.89	0.19	1.96	-	2.16	9.73	2.49
Vehicles	69.37	42.57	-	111.93	11.67	8.22	-	19.89	92.04	57.70
Office Equipment	0.12	6.23	-	6.35	0.01	0.66	-	0.67	5.68	0.11
Electrical Equipment	-	15.77	-	15.77	-	0.46	-	0.46	15.32	-
Roads	-	180.62	-	180.62	-	9.54	-	9.54	171.08	-
Total	72.17	15,604.49	-	15,676.66	11.87	311.88	-	323.76	15,352.90	60.29

Property, Plant and Equipment as at 31st March, 2025

Particulars	Gross Block				Depreciation				Net Block	
	Balance as at 01.04.2024	Additions	Disposals	Balance as at 31.03.2025	Upto 01.04.2024	For the period	On disposals	Total upto 31.03.2025	Balance as at 31.03.2025	Balance as at 31.03.2024
Plant and equipment	-	-	-	-	-	-	-	-	-	-
Furniture and Fixtures	-	-	-	-	-	-	-	-	-	-
Computers	-	2.68	-	2.68	-	0.19	-	0.19	2.49	-
Vehicles	49.17	20.20	-	69.37	6.23	5.45	-	11.67	57.69	42.94
Office Equipment	-	0.12	-	0.12	-	0.01	-	0.01	0.11	-
Total	49.17	23.00	-	72.17	6.23	5.65	-	11.88	60.29	42.94

2.01 a: No Property, plant and equipment was kept temporarily idle during the year under report.

2.01 b: All the Property, plant & equipments are owned by the company. Further, no proceedings have been initiated or pending against the company,

for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended from time to time) and the rules made thereunder.

2.01 c: The company has not revalued its Property, plant & equipment (including Right of Use assets) during the year under report and the immediately preceding previous year.

2.01d: There are no intangible assets under development as at 31st March 2026. (Previous year - Nil)

2.04 Other Intangible assets as at 31st March, 2026

Particulars	Gross Block				Amortization				Net Block	
	Balance as at 01.04.2025	Additions	Disposals	Balance as at 31.03.2026	Upto 01.04.2025	For the period	On disposals	Total upto 31.03.2026	Balance as at 31.03.2026	Balance as at 31.03.2025
Software	-	1.09	-	1.09	-	0.04	-	0.04	1.05	-
Total	-	1.09	-	1.09	-	0.04	-	0.04	1.05	-



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended March 31, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.03 Right of Use Assets

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Balance as at beginning of the year	77.16	64.43
Additions		14.83
Disposals	-	-
Amortisation	1.42	2.10
Balance as at the end of the year	75.74	77.16

ROU Assets for the year ended 31-03-2026

Particulars	Amount (₹)
ROU Asset - Taken for the purpose of Manufacturing Facility by payment of ₹ 1,50,000 as a one time payment for 99 years from an individual.	1.44
ROU Asset - Taken for the purpose of Manufacturing facility with an annual payment of ₹ 78750 for a period of 90 Years.	62.31
ROU Asset - Taken for the purpose of Pipe Line work from the Government of Odisha for the period of 20 years with one time payment of ₹13,33,045.	12.00
Total	75.74

ROU Assets for the year ended 31-03-2025

Particulars	Amount (₹)
ROU Asset - Taken for the purpose of Manufacturing Facility by payment of ₹ 1,50,000 as a one time payment for 99 years from an individual.	1.45
ROU Asset - Taken for the purpose of Manufacturing facility with an annual payment of ₹ 78750 for a period of 90 Years.	63.04
ROU Asset - Taken for the purpose of Pipe Line work from the Government of Odisha for the period of 20 years with one time payment of ₹13,33,045.	12.66
Total	77.16



2.03a. Lease Liability Obligation*(i) As Lessee***(A) Movement in lease liabilities**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Balance as at the beginning of the year	9.26	10.84
Additional lease obligations recognised	-	-
Unused amounts reversed	-	1.60
Interest expense on lease liabilities	0.79	0.79
Amounts paid during the year	0.79	0.76
Balance as at the end of the year	9.26	9.26

(B) Maturity analysis of Lease Liabilities

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Less than 1 year	0.79	0.79
1 to 5 years	3.15	3.15
More than 5 years	54.24	55.02
Total undiscounted lease liabilities at 31 March 2025	58.18	58.96
Lease liabilities included in the statement of financial position at the end of the financial year	9.26	9.26
Current	0.79	0.79
Non Current	8.47	8.49

(C) Amounts recognised in profit or loss

Particulars	31-03-26	31-03-25
Interest on lease liabilities (excluding amortisation of Right to Use)	0.79	0.76
Variable lease payments not included in the measurement of lease liabilities	-	-
Income from sub-leasing right-of-use assets	-	-
Expenses relating to short-term leases	1.50	-
Expenses relating to leases of low-value assets, excluding short-term leases of low value assets	15.50	-



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March 2026

(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.02 Capital work in progress

Particulars	As at March 31, 2026	As at March 31, 2025
a. Balance at the beginning of the year	13,477.92	7,384.04
b. Add: Additions during the year	2,999.79	4,411.05
c. Less: Capitalised during the year	16,477.71 16,418.76	11,795.09 -
d. Balance at the end of the year	58.95	11,795.09
e. Expenditure incidental to construction awaiting allocation to PPE	-	1,682.84
Total (d+e)	58.95	13,477.92

2.02a Expenditure incidental to construction awaiting allocation

Particulars	As at March 31, 2026	As at March 31, 2025
a. Balance at the beginning of the year	1,682.84	562.10
b. Add: Net Expenditure incurred during the year		
Interest on Specified Borrowings	440.61	820.27
Professional & Consultancy Charges	3.86	81.57
Electricity Charges	12.71	17.07
Transportation, Accommodation & Other Charges	13.95	15.38
Employee Costs	56.74	113.73
Rent Rates & Taxes	15.41	11.22
Others	11.64	61.50
	554.91	1,120.74
c. Less: Capitalised during the year	2,237.75	-
Expenditure awaiting allocation to fixed assets	-	1,682.84

Note No 2.02(a)(i): The Company's Grain based Ethanol distillery project, Odisha commenced commercial production on 09 September 2025.

Accordingly, the expenditure incurred on the project up to the date of commencement of commercial production has been capitalised in accordance with the applicable Indian Accounting Standards.

Note No.2.02(a)(ii): The capitalization rate used to determine the amount of borrowing costs eligible for capitalization is 9.28% and Previous year is 10.21% p.a.

2.02b Capital work in progress Ageing Schedule

As on 31st March 2026

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects/ Assets in progress					
New Storage Shed	33.54	-	-	-	33.54
Syrup Tanker	25.41	-	-	-	25.41
Projects temporarily suspended	-	-	-	-	-

As on 31st March, 2025

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress					
Grain based Ethanol Distillery, Odisha	5,531.78	6,687.13	1,259.01	-	13,477.92
Projects temporarily suspended	-	-	-	-	-

2.02c. Capital work in progress Completion schedule

As on 31st March 2026

CWIP	To be completed in				Remarks
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects/ Assets in progress					
New Storage Shed	33.54	-	-	-	Project/ Assets completion is not overdue and also has not exceeded its initial estimated costs
Syrup Tanker	25.41	-	-	-	
Projects temporarily suspended	-	-	-	-	



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

As on 31st March, 2025

CWIP	To be completed in				Remarks
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress					
Grain based Ethanol Distillery, Odisha	13,477.92	-	-	-	Project completion is not overdue but has exceeded its initial costs by ₹ 660 Lakhs (Co2 Plant - ₹ 360 Lakhs & Raw water pipe line - ₹ 300 Lakhs)
Projects temporarily suspended					

2.05 Financial assets - Others

Particulars	As at March 31, 2026	As at March 31, 2025
Security Deposits	66.32	34.82
Total	66.32	34.82

2.06 Other Non Current Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Advances for Capital Works	0.17	1,058.43
Advances paid to others	345.82	81.00
Total	345.99	1,139.43

2.07 Inventories

Particulars	As at March 31, 2026	As at March 31, 2025
(At lower of cost and net realisable value)		
Raw Materials	957.44	30.17
Raw Materials in Transit	67.78	-
Finished Goods	782.63	-
Stores, Spares and Consumables	145.94	-
Total	1,953.78	30.17

2.08 Trade Receivables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade receivables		
Unsecured, considered good	2,917.49	-
Total	2,917.49	-

Ageing schedule of Trade Receivables as at 31st March, 2026

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	2,381.89	535.59	-	-	-	-	-
(ii) Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - credit impaired	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables-considered good	-	-	-	-	-	-	-
(v) Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade Receivables - credit impaired	-	-	-	-	-	-	-



COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

Ageing schedule of Trade Receivables as at 31st March, 2025

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good	-	-	-	-	-	-	-
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables-considered good	-	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-

2.09 Cash & Cash Equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with Banks		
- In Current Accounts	384.25	41.23
Cash on hand	0.09	0.28
Total	384.34	41.52

2.10 Bank balances other than above

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with Banks		
- Deposits with original maturity of more than three months but less than 12 months	305.71	94.54
- Deposits with original maturity of more than 12 months	694.93	815.63
- to the extent held as margin money against guarantees	50.00	4.16
Total	1,050.64	914.33

2.11 Other Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Deposits Recoverable	-	-
Total	-	-

2.12 Current Tax Assets (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Prepaid Taxes (Net of Provision for Income Tax)	326.16	-
Total	326.16	-

2.13 Other current assets

Particulars	As at March 31, 2026	As at March 31, 2025
Prepaid expenses	12.16	23.03
Income tax Refund Receivable	5.68	5.68
GST Input Receivable	1,127.51	1,937.03
Other assets	561.20	3.27
Total	1,706.54	1,969.01



COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Notes to Financial Statements for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.14 Equity share capital

Particulars	As at March 31, 2026	As at March 31, 2025
Authorised		
3,00,00,000 (March 31, 2025: 3,00,00,000) Equity shares of Rs.10/- each	3,000.00	3,000.00
Total	3,000.00	3,000.00
Issued, Subscribed and Paid Up		
2,81,00,000 (March 31, 2025: 2,81,00,000) Equity share of Rs.10/- each fully paid up	2,810.00	2,810.00
Total	2,810.00	2,810.00

2.14a Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	As at March 31, 2026		As at March 31, 2025	
	No.	Rs.	No.	Rs.
Equity Shares of Rs.10 each fully paid up				
Outstanding at the beginning of the year	2,81,00,000.00	2,810.00	2,80,00,000.00	2,800.00
Add : Equity shares allotted	-	-	1,00,000.00	10.00
Outstanding at the end of the year	2,81,00,000.00	2,810.00	2,81,00,000.00	2,810.00

2.14b Rights attached to Equity Shares

The Company has only one class of equity shares having a par value of Rs. 10/- per share. Holder of each equity shares is entitled to one vote per share at the general meetings of the Company. In the event of Winding up of the company, the holders of equity shares are eligible to receive share in the remaining assets of the company after distribution of all preferential amounts in proportion to their share holding. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting.

2.14c Details of Shareholders holding more than 5% shares of the Company:

Particulars	As at March 31, 2026		As at March 31, 2025	
	% Holding	No.	% Holding	No.
Equity Shares of Rs. 10/- each Held By				
M/s.Coastal Corporation Limited (Holding Company)	100.00	2,81,00,000	100.00	2,81,00,000

2.14d Shareholding of Promoters

As at 31st March, 2026				
Promoter name	No. of Shares held	% of total shares	% Change	
M/s.Coastal Corporation Limited (Holding Company)	2,81,00,000	100.00%	0.00%	
Total	2,81,00,000	100.00%	0.00%	

As at 31st March, 2025			
Promoter name	No. of Shares held	% of total shares	% Change during the year
M/s.Coastal Corporation Limited (Holding Company)	2,81,00,000	100.00%	0.36%
Total	2,81,00,000	100.00%	0.36%

2.15 Other Equity

Particulars	As at March 31,2026	As at March 31, 2025
a) Securities Premium	-	-
b) General reserve	1,358.15	(24.64)
c) Retained Earnings		
Total	1,358.15	(24.64)

Nature of reserves:

- a) Securities premium : Securities premium represents premium received on issue of shares. The reserve is utilised in accordance with the provisions of Companies Act, 2013.
b) General reserve : The general reserve is created by way of transfer of part of the profits before declaring dividend pursuant to the provisions of Companies Act, 2013.
c) Retained Earnings : Retained earnings generally represents the undistributed profit amount of accumulated earnings of the company.



COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Notes to Financial Statements for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.16 Non Current Financial Liabilities - Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
Secured Loans :		
HDFC Term Loan (Repayable in 16 quarterly instalments of Rs. 687.5 Lakhs starting from 04-07-2025, secured by mortgage of land and buildings owned by the company, hypothecation of Plant & Machinery & entire current assets of the company,	6,253.92	8,336.88
HDFC Vehicle Loan - 3 No's (Repayable in 39 monthly instalments of Rs. 0.23 Lakhs starting from 12-04-2025 and 39 monthly instalments of Rs. 0.24 Lakhs starting from 12-04-2025, received loan on hypothecation of Vehicles)	34.21	9.98
Unsecured Loans		
Interest Free Loan from Parent Company	2395.15	2,177.48
Total	8,683.27	10,524.35

2.17 Deferred Tax Liability (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Major component of Deferred Tax Liability arising on account of timing difference is:		
Liabilities:		
Difference between tax and book depreciation	370.32	-
Total	370.32	-

2.18 Current Financial Liabilities - Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
Secured		
Loan repayable on demand from a Bank (Secured by hypothecation on the entire current assets of the company, both present and future. Further, secured by collateral of a residential building of a holding company.)	6,015.35	1,007.35
Current Maturities of Long term Borrowings	2,756.25	2,755.49
Total	8,771.61	3,762.84

Note 2.18(a)

(a) The company has not been declared as a wilful defaulter by any bank or financial institution or other lender.

(b) The quarterly returns /statements of current assets filed by the Company with banks are in agreement with the books of account, except for the quarter ended 31st December 2025. Sum reconciliation is detailed as under:

Name of Bank	Particulars of Securities provided	Quarter ended	Amount as per Books of account	Amount as reported in quarterly statements	Amount of difference	Reasons
HDFC Bank	Debtors	Dec-25	2,356.50	2,350.00	6.50	While reporting to the banker, Sales reported were less, whereas in the books of account sales were reported after rectification.

The carrying amounts of financial and non-financial assets pledged as security for current and non-current borrowings are disclosed in note 2.34

2.19 Current Financial Liabilities - Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of Micro and Small Enterprises	0.56	2.96
Total outstanding dues of creditors other than Micro and Small Enterprises	2,091.74	635.13
Total	2,092.30	638.10

Dues to Micro and Small Enterprises:

Particulars	As at March 31, 2026	As at March 31, 2025
(a) the principal amount remaining unpaid to any supplier as at the end of each accounting year	0.07	2.80
(b) the interest due on above principal amount remaining unpaid to any supplier as at the end of each accounting year	-	-
(c) the amount of interest paid by the buyer under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
(d) The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006)	0.32	0.17
(e) The amount of interest accrued and remaining unpaid at the end of accounting year	0.49	0.17
(f) The amount of further interest remaining due and payable even in the succeeding year, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23 of MSMED Act 2006.	-	-



COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Notes to Financial Statements for the period ended 31st March 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.19a Ageing schedule of Trade payables as at 31st March, 2026

Particulars	Outstanding for the following periods from the due date of payment or date of transaction					Total
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	0.07	0.32	0.17	-	-	0.56
(ii) Others	1,040.10	1,050.00	1.64	-	-	2091.74
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

Ageing schedule of Trade payables as at 31st March, 2025

Particulars	Outstanding for the following periods from the due date of payment or date of transaction					Total
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	2.96	-	-	-	-	2.96
(ii) Others	-	635.13	-	-	-	635.13
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

2.19b There are no unbilled dues as at 31st March 2026 (Previous year: ₹. Nil)

2.20 Current Financial Liabilities - Others

Particulars	As at March 31, 2026	As at March 31, 2025
Other liabilities	122.58	12.11
Total	122.58	12.11

2.21 Current Financial Liabilities - Others

Particulars	As at March 31, 2026	As at March 31, 2025
Provisions	7.02	-
Gratuity Liability	7.02	-
Total	7.02	-

2.22 Other Current Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Statutory dues payable	10.94	4.26
Other liabilities	4.44	0.50
Total	15.38	4.76

2.23 Current Tax Liabilities (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for Income tax Liability	-	13.14
Less:	-	-
Current Tax Assets	-	5.26
Current Tax Liability (Income tax payable)	-	7.88



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026

(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.24 Revenue from Operations

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Sale of Products		
Income from Sale of Ethanol	21,086.77	-
(A)	21,086.77	
Other Operating Revenue		
Income from Sale of DDGS	2,989.81	-
Income from Sale of Dryer syrup	2.74	-
Income from Sale of CO2	3.10	-
(B)	2,995.65	-
Revenue from Operations (A+B)	24,082.42	-

(A) Revenue disaggregation by industry vertical is as follows:

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Fixed price contracts	24,082.42	-
Total	24,082.42	-

(B) Revenue disaggregation by geography is as follows:

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
a. Domestic	24,082.42	-
b. Exports	-	-
Total	24,082.42	-

(C) Reconciliation of revenue recognized with the contracted price with customers is as follows

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Gross Revenue	24,082.42	-
Less: Sales Returns	-	-
Less: Amounts adjusted for Discounts, rebates, refunds etc	-	-
Revenue recognised in the statement of profit and loss	24,082.42	-

(D) Changes in advances received from customers (Contract liability) are as follows:

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Balance at the beginning of the year	-	-
Add: Amounts received during the year	-	-
Less: Revenue recognised during the year	-	-
Balance at the end of the year (Net)	-	-

(E) The details in respect of percentage of revenues generated from top customers are as follows:

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Revenue from 1st top customer	4,854.95	-
Revenue from 2nd top customer	4,571.11	-
Revenue from 3rd top customer	4,111.90	-
Revenue from 4th top customer	2,394.94	-
Total of other customers generating more than 10% revenue	8,149.53	-



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026

(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.25 Other Income

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Interest on financial assets measured at cost		
Interest on Bank Deposits	54.93	53.96
Income from sale of Scrap	108.52	-
Other Misc Income	-	0.02
Interest Subsidy from NABARD	228.86	-
Total	392.31	53.98

2.26 Cost of Materials Consumed

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Raw Materials Consumed		
Stock at the beginning of the year	30.17	-
Add : Purchases	22,231.48	30.17
	22,231.48	30.17
Less : Stock at the end of the year	1,171.15	30.17
	21,090.50	-

(A) Details of Raw Materials consumed

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Broken Rice	17,975.67	-
Chemicals	25.39	-
Coal	2,396.62	-
Enzymes	543.49	-
Husk	67.63	-
Technical Grade Urea	81.70	-

2.27 (Increase)/Decrease in Inventories of Finished Goods

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Opening stock of inventories		
Finished goods	-	-
Closing stock of inventories		
Finished goods	782.63	-
	782.63	-
Decrease/(Increase) in inventories of finished goods	(782.63)	-

2.28 Operating expenses

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Consumption of stores, spares and consumables	32.72	-
Power & Fuel	31.17	-
Repairs and maintenance:		
- Plant and Machinery	208.87	-
- Vehicles	-	0.98
Direct wages	93.51	-
Other operating charges	295.15	-
Total	661.42	0.98



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.29 Employee Benefits Expenses

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Salaries, allowances and wages	226.69	-
Contribution to provident fund and other funds	3.48	-
Gratuity expenses	7.02	-
Staff welfare expenses	1.32	-
Total	238.52	-

Employee benefit plans:

As per Indian Accounting Standard 19 "Employees' Benefits", the disclosures of Employee Benefits as defined in the Standard are given hereunder:

Defined Contributions Plans:

Contributions to Defined Contribution plans, recognized as expense for the year,

Particulars	2025-26	2024-25
Employer's Contributions to Provident and Other Funds	3.48	-

Defined Benefit Plans:

A. The company provides for gratuity to the employees as per Payment of Gratuity Act, 1972. Permanent employees who are in continuous service for a period of 5 years (except in case of death or disablement) are eligible for gratuity. While Fixed Term Employees (FTE) are eligible on pro-rata basis after 1 year of continuous service. The amount of gratuity is payable on retirement/resignation. The gratuity plan is a funded plan and the company makes contributions to recognised funds in India.

B. The employees' gratuity fund scheme managed by the Company is a defined benefit plan. The present value of obligation is determined based on actuarial valuation using the "Projected Unit Credit Method" which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

I. Reconciliation of opening and closing balances of Defined Benefit obligations

Particulars	Gratuity (Unfunded)	
	31 March, 2026	31 March, 2025
Defined Benefit obligation at beginning of the year	-	-
Interest Cost	-	-
Current Service Cost	3,02,706.00	-
Past Service Cost	3,99,580.00	-
Benefits paid	-	-
Actuarial loss / (gain) on obligation	-	-
Defined Benefit obligation at year end	7,02,286.00	-

II. Reconciliation of opening and closing balances of fair value of plan assets

Particulars	Gratuity (Unfunded)	
	31 March, 2026	31 March, 2025
Fair value of plan assets at beginning of the year	-	-
Interest Income	-	-
Contributions	-	-
Benefits paid	-	-
Remeasurements - Return on Assets (Excluding Interest Income)	-	-
Fair value of plan assets as at the end of the year	-	-

III. Reconciliation of fair value of assets and obligations as at the end of the financial year

Particulars	Gratuity (Unfunded)	
	31 March, 2026	31 March, 2025
Fair value of plan assets	-	-
Present value of obligation	7,02,286.00	-
Amount recognized as liability in Balance sheet	(7,02,286.00)	-



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

IV. Expenses recognized during the year in the Statement of Profit & Loss under employee benefit expenses

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
Current Service Cost	3,02,706.00	-
Past Service Cost	3,99,580.00	-
Interest Cost	-	-
Expected return on plan assets	-	-
Actuarial (gain)/ loss	-	-
Expenses recognized in the statement of Profit & Loss	7,02,286.00	-

V. Amount to be recognized in statement of other comprehensive income

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
Remeasurements of the net defined benefit liability/ (asset)	-	-
(Return)/loss on plan assets excluding interest income	-	-
Expenses recognized in the statement of Other Comprehensive Income	-	-

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
(Gain)/loss from change in demographic assumptions	-	-
(Gain)/loss from change in financial assumptions	-	-
(Gain)/loss from change in experience adjustments	-	-

VI. Significant estimates: actuarial assumptions

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
Discount rate	7.80%	-
Salary escalation rate	10%	-
Mortality rate	100%	-
Withdrawal rate	3%	-

VII. Maturity Profile of Defined Benefit Obligations:

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
Expected outflow in year1	51215.00	-
Expected outflow in year2	14522.00	-
Expected outflow in year3	17213.00	-
Expected outflow in year4	22523.00	-
Expected outflow in year5	25798.00	-
Expected outflow in year6	72976.00	-
Expected outflow in year7	27557.00	-
Expected outflow in year8	29516.00	-
Expected outflow in year9	31631.00	-
Expected outflow in year10	33917.00	-



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

VIII. Significant estimates : Sensitivity analysis

Discount rate, Salary Escalation Rate and Attrition/Withdrawal rate are significant

Particulars	Effect on Gratuity valuation	
	31 March,2026	31 March,2025
Impact on present value of defined benefit obligation if		
- discount rate increase by	609238.00	-
- discount rate decrease by	816763.00	-
- salary increase by	769627.00	-
- salary decrease by	642486.00	-
- withdrawal/attrition increase by	700782.00	-
- withdrawal/attrition decrease by	701385.00	-

IX. Other Disclosures

Particulars	Gratuity (Unfunded)	
	31 March,2026	31 March,2025
Discontinuance liability	360577.00	-

As per the enterprise's accounting policy actuarial gains and losses are recognized immediately during the same year itself.
The above information is certified by the Actuary.

2.30 Finance charges

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Interest paid to banks on		
Term Loans	529.12	0.08
Overdraft facility	199.69	-
Finance charges on Lease Liabilities	0.59	-
Interest paid to Micro and small enterprises	0.32	0.17
Bank charges	9.01	-
Total	738.72	0.24

2.31 Depreciation and Amortisation

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Depreciation on plant, property and equipment	311.92	5.64
Amortisation on right-of-use assets	1.22	-
Total	313.14	5.64

2.32 Other Expenses

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Insurance	27.96	0.16
Rent, Rates & Taxes	18.73	-
Repairs & maintenance on Vehicles	36.05	-
Telephone and Communication expenses	1.02	-
Impairment loss allowance	8.36	-
Auditors' Remuneration		
for Audit Fees	2.50	0.50
for Taxation Matters	-	-
Professional and Consultancy charges	37.51	-
Selling and Distribution expenses	268.68	-
Corporate Environmental Expenditure (C.E.R)	1.70	31.92
Prior period expenditure	15.27	-
Travelling and conveyance expenses	20.27	0.78
Miscellaneous Expenses	27.38	27.43
Total	465.45	60.79



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.33 Income Tax Expense

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Current tax		
- Based on Provision u/s 115BAA of the Income Tax Act, 1961	-	13.14
Deferred tax		
Decrease /(increase) in Deferred Tax Assets	-	-
Increase /(decrease) in Deferred Tax Liability	370.32	-
Total Income Tax Expense	370.32	13.14

(A) Deferred Tax Expense/ (Income)

Expense/ (Income) recognised for the year ended	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Deferred tax (liability)/ Asset recognised in statement of profit or loss	370.32	-
Deferred tax (liability)/ Asset recognised in Other Comprehensive Income	-	-
Deferred tax recognised in Total Comprehensive Income	370.32	-

(B) Reconciliation of tax expense and the accounting profit multiplied by tax rate

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Profit from continuing operation before income tax expense	1,749.61	(13.67)
Profit from discontinuing operation before income tax expense	-	-
Total	1,749.61	(13.67)
Tax @25.17%	440.34	(3.44)
Tax effect of amount which are not deductible (taxable) in calculating		
Amortization of intangibles	-	-
Corporate social responsibility expenditure	-	8.03
Contingent consideration	-	-
Other Items	4.62	8.55
Differences in Domestic tax rates	-	-
Adjustments of current tax of prior periods	-	-
Tax losses for which no deferred income tax was recognised	(74.64)	-
Previously unrecognised tax losses now recouped to reduce current tax expense	-	-
Previously unrecognised tax losses used to reduce deferred tax expenses	-	-
Income Tax expense	370.32	13.14



COASTAL BIOTECH PRIVATE LIMITED

CIN: U24290OR2021PTC035710

Notes to Financial Statements for the period ended 31st March, 2026
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

(C) Components of Tax expense

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
a) Current tax expense	-	13.14
b) Amount of deferred tax expense (income) relating to the origination and reversal of temporary differences	370.32	-
c) Amount of deferred tax expense (income) relating to changes in tax rates or the imposition of new taxes	-	-
d) Amount of the benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense	-	-
e) Amount of the benefit from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense	-	-

2.34 Particulars of Earnings Per Share

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Profit attributable to equity holders:		
Continuing operations	1382.79	(26.81)
Discontinued operation	-	-
Profit attributable to equity holders of the parent for basic earnings	1382.79	(26.81)
Interest on convertible preference shares	-	-
Profit attributable to equity holders of the parent adjusted for the effect of dilution	1382.79	(26.81)

Particulars	For the year ended 31st March, 2026	For the year ended 31st March, 2025
Weighted average number of Equity shares for basic EPS*	2,81,00,000	2,80,52,603
Effect of dilution	-	-
Share options	-	-
Convertible preference shares	-	-
Weighted average number of Equity shares adjusted for the effect of dilution	2,81,00,000	2,80,52,603

* The weighted average number of shares takes into account the weighted average effect of changes in treasury share transactions during the year. There have been no other transactions involving Equity shares or potential Equity shares between the reporting date and the date of authorisation of these financial statements

Earnings per equity share (for continuing operations)	For the year ended 31st March, 2026	For the year ended 31st March, 2025
a) Basic	4.92	(0.10)
b) Diluted	4.92	(0.10)



COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Balance Sheet as at 31st March 26
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

2.35

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
(i) Contingent Liabilities		
<i>Claims against the company not acknowledged as debt</i>		
Outstanding Guarantees to Banks for supplier's payments	317.09	-
(ii) Commitments		
Estimated amount of contracts remaining to be executed on capital account and not provided for	43.25	-

2.36 Assets pledged as security

The carrying amounts of assets pledged as security for current and non current borrowings are:

Particulars	Notes	March 31, 2026	March 31, 2025
Current assets			
<i>Financial assets</i>			
Trade receivables	2.07	2,917.49	-
Cash & cash equivalents	2.08	384.34	41.52
Bank balances other than above (ii)	2.09	1,050.64	914.33
<i>Non-financial assets</i>			
Inventories	2.06	1,953.78	30.17
Other Current assets	2.11	1,706.54	1,969.01
Non-Current Assets			
Plant & Machinery	2.01	10,471.69	-
Buildings	2.01	4,579.46	-

2.37 Segment information

The Company operates only in one business segment being the manufacture of ethanol and there are no geographical segments to be reported.

2.38 Related Party Disclosures

As per Indian Accounting Standard 24 "Related parties disclosure" the disclosure of Related parties as defined in the Standard are given hereunder:

(i) Names of related parties and description of relationship

Name of the Related Party	Relationship
(a) Sri T. Valsaraj	KMP (Director)
(b) Sri.G.V.V.Satyanarayana	KMP (Director)
(c) M/s. Vineesha Valsaraj	KMP (Director)
(d) M/s. Coastal Corporation Limited	Holding Company
(e) M/s Coastal Developers Pvt Ltd	Significant Influence

(ii) Transactions during the year with related parties

Name of the Party	Relationship	Nature of transaction	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Miss.Vineesha Valsaraj	KMP (Director)	Remuneration	30.00	30.00
Coastal Corporation Limited	Holding Company	Unsecured loan	2,395.15	2,177.48
Coastal Developers Private Limited	Significant influence	Civil works	1,253.02	260.63

(iii) Balance Outstanding

Name of the Party	Relationship	Nature of transaction	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Coastal Corporation Limited	Holding Company	Unsecured loan	2,395.15	2,177.48
Coastal Developers Private Limited	Significant influence	Civil works	307.90	459.19

Note: All the aforesaid related party transactions were carried on arms' length basis



2.39 **Impairment of Assets**
According to an internal technical assessment carried out by the Company, there is no impairment in the carrying cost of cash generating units of the Company in terms of Indian Accounting Standard 36 'Impairment Of Assets'

2.40 **Balances Outstanding**
Loans and Advances, Trade Receivables and Trade Payables are subject to confirmation.

2.41 **Financial Ratios**

Particulars	Numerator	Denominator	Current Period	Previous Period	% of variance*	Remarks for change in the ratio by more than 25%
Liquidity Ratio						
Current Ratio (times)	Total Current assets	Total Current liabilities	0.76	0.67	13.457	Due to increase in borrowings, Trade receivables and inventory
Solvency Ratio						
Debt-Equity Ratio (times)	Total debt, debt consists of borrowings and lease liabilities	Total equity	4.69	5.36	(12.49)	Due to increase in borrowings and trade payables
Debt Service Coverage Ratio (times)	Earnings before interest, tax, depreciation & non cash expenditure, income	Debt service = Interest and lease payments + Principal repayments	0.29	(0.05)	(707.59)	Due to profit during the year
Profitability ratio						
Net Profit Ratio (%)	Total comprehensive income	Revenue from operations	5.74	0.00	-	NA
Return on Equity Ratio (%)	Total comprehensive income	Average total equity	39.77	(0.96)	(4,245.02)	Due to profit during the year
Return on Capital employed (%)	Earnings before interest and tax	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability	10.05	(0.10)	(10,087.55)	Due to earnings during the year and increase in debt
Return on Investment (%)	Income generated from invested funds & change in market value of investments	Average Invested funds	5.52	6.27	(12.04)	Due to increase in Fixed deposits
Utilization Ratio						
Trade Receivables turnover ratio (times)	Revenue from operations	Average trade receivables	16.51	0.00	-	
Inventory turnover ratio (times)	Cost of Goods sold	Average Inventory	24.67	0.00	-	
Trade payables turnover ratio (times)	Net credit purchases	Average Trade Payables	16.28	0.09	17,123.02	Due to increase in purchase of materials during the year
Net capital turnover ratio (times)	Revenue from operations	Average working capital (i.e. Total current assets less Total current liabilities)				NA



2.42

Other additional Regulatory information

- a) The company has no transactions with struck off companies under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.
- b) In respect of various loans charges/ satisfaction of charges have been registered with Registrar of Companies within the statutory period prescribed under the Act.
- c) The Company has no subsidiary companies and accordingly, the provisions of clause (87) of the section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017 are not applicable.
- d) There is no Scheme of Arrangements that has been approved in terms of sections 230 to 237 of the Companies Act, 2013.
- e) No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- f) The company has not granted any Loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person that are repayable on demand or without specifying any terms or period of repayment.
- g) There are no transactions that are not recorded in the books of account and have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- h) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year

2.43

As the company's net worth, turnover or net profit are within the threshold limit for incurring expenditure under Corporate Social Responsibility activities. So the provisions of section 135 of the Companies Act, 2013, are not applicable

2.44

Recent Accounting Pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On August 13, 2025, MCA notified the Companies (Indian Accounting Standards) Second Amendment Rules, 2025, as below:

Ind AS 1 - Presentation of Financial Statements:

The existing carve-out from IAS 1 regarding classification of liabilities when there is a breach of material covenant that transforms the liability from non current to current, has been removed. If there is a breach of a covenant of a long-term loan arrangement on or before the end of the reporting date with the effect that the liability becomes payable on demand, the waiver obtained from the lender on or before the reporting date will be required to continue classifying the liability as non-current. Any waiver granted by the lender after the reporting date will be treated as a non-adjusting event. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2026. The impact of the amendment is insignificant in the financial statements.

Ind AS 10 - Events after the Reporting Period:

This amendment removes the previous provision that allowed an entity to treat a lender's waiver of a covenant breach (received after the reporting date but before approval) as an adjusting event. If a loan is repayable on demand due to a breach on the balance sheet date, it must be classified as current, even if a waiver is obtained later. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2026. The impact of the amendment is insignificant in the financial statements.

Supplier Finance Arrangement

The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

Income Taxes - International Tax Reform - Pillar Two Model Rules

The amendment to Ind AS 12 provide temporary exception to recognition and disclosure of information about deferred tax assets and liabilities related to Pillar Two income taxes. Based on the assessment of company's operations and the jurisdictional tax rates, the company is not subject to Pillar two income taxes. This relief is immediate and applies retrospectively, it does not have any significant impact in its financial statements.

2.45

Previous year figures were regrouped wherever necessary to make them comparable with current year figures.

As per the report of even date

for, and on behalf of the Board

for, Brahmayya & Co
Chartered Accountants
Firm Reg. No. 0005135

Partner
C.V. Ramana Rao
Partner
Membership No. 0118545
Place: Visakhapatnam
Date: 30.05.2026



G.V.V. Satyanarayana
Director (Finance) & CFO
(DIN: 0000187006)

Swarupa Meruva
Company Secretary

T. Valsaraj
Director & Chairman
(DIN: 0000057558)

COASTAL BIOTECH PRIVATE LIMITED
CIN: U24290OR2021PTC035710
Balance Sheet as at 31st March 26
(All amounts in Lakhs Rupees except for share data or as otherwise stated)

3. FINANCIAL INSTRUMENTS

3.1 Financial instruments by category

The carrying value and fair value of financial instruments by categories as of March 31, 2026 were as follows:

Particulars	Amortized cost	Measured at fair value through profit or loss		Measured at fair value through OCI		Total carrying value	Total Fair value
		Designated upon initial recognition	Mandatory	Designated upon initial recognition	Mandatory		
Assets:							
Cash and cash equivalents	384.34	-	-	-	-	384.34	384.34
Trade receivables	2,917.49	-	-	-	-	2,917.49	2,917.49
Bank balances and others	1,050.64	-	-	-	-	1,050.64	1,050.64
Total	4,352.46	-	-	-	-	4,352.46	4,352.46
Liabilities:							
Trade payables	2,092.30	-	-	-	-	2,092.30	2,092.30
Other financial liabilities	17,577.46	-	-	-	-	17,577.46	17,577.46
Total	19,669.76	-	-	-	-	19,669.76	19,669.76

The carrying value and fair value of financial instruments by categories as of March 31, 2025 were as follows:

Particulars	Amortized cost	Measured at fair value through profit		Measured at fair value through OCI		Total carrying value	Total Fair value
		Designated upon initial recognition	Mandatory	Designated upon initial recognition	Mandatory		
Assets:							
Cash and cash equivalents	41.52	-	-	-	-	41.52	41.52
Trade receivables	-	-	-	-	-	-	-
Other financial assets -bank balances and others	914.33	-	-	-	-	914.33	914.33
Total	955.85	-	-	-	-	955.85	955.85
Liabilities:							
Trade payables	638.10	-	-	-	-	638.10	638.10
Other financial liabilities	14,299.30	-	-	-	-	14,299.30	14,299.30
Total	14,937.39	-	-	-	-	14,937.39	14,937.39

3.2 Fair Valuation Techniques

The fair values of the financial assets and liabilities are included at the amount that would be received on sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

A) The following methods and assumptions were used to estimate the fair values

The fair value of cash and cash equivalents, trade receivables and payables, financial liabilities and assets approximate their carrying amount largely due to the short-term maturities of these instruments. The management considers that the carrying amounts of financial assets and financial liabilities recognised at nominal cost/amortised cost in the financial statements approximate their fair values.

B) Fair value hierarchy

The fair value of financial instruments as referred to above note have been classified into three categories depending on the inputs used in the valuation technique. The hierarchy gives the highest priority to quoted prices in active markets for identified assets or liabilities [Level 1 measurements] and lowest priority to unobservable inputs [Level 3 measurements].

The categories used are as follows:

Level 1: Level 1 hierarchy includes inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

Level 2: Inputs that are observable either directly or indirectly for the asset or liability, other than quoted prices included within level 1.

Level 3: Inputs for the asset or liability which are not based on observable market data (unobservable inputs).



3.3 Offsetting financial assets and financial liabilities as on March 31, 2026

Particulars	Effects of offsetting on the balance sheet			Related amounts not set off		Net amount
	Gross amount	Gross amounts set off in the balance sheet	Net amounts presented in the balance sheet	Amounts subject to master netting arrangements	Financial instruments collateral	
Financial assets						
Cash and cash equivalents	384.34	-	384.34	-	384.34	-0.00
Trade receivables	2,917.49	-	2,917.49	-	2,917.49	-0.00
Other financial assets	1,050.64	-	1,050.64	-	1,050.64	-0.00
Financial liabilities						
Trade payables	2,092.30	-	2,092.30	-	-	2,092.30
Other financial liabilities	17,577.46	-	17,577.46	-	-	17,577.46
Derivative financial instruments	-	-	-	-	-	-

Offsetting financial assets and financial liabilities as on March 31, 2025

Particulars	Effects of offsetting on the balance sheet			Related amounts not set off		Net amount
	Gross amount	Gross amounts set off in the balance sheet	Net amounts presented in the balance sheet	Amounts subject to master netting arrangements	Financial instruments collateral	
Financial assets						
Cash and cash equivalents	41.52	-	41.52	-	41.52	-0.00
Trade receivables	-	-	-	-	-	-
Other financial assets	914.33	-	914.33	-	914.33	0.00
Derivative financial instruments	-	-	-	-	-	-
Financial liabilities						
Trade payables	638.10	-	638.10	-	-	638.10
Other financial liabilities	14,299.30	-	14,299.30	-	-	14,299.30
Derivative financial instruments	-	-	-	-	-	-

3.4 Financial risk management framework

A) The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Board of Directors monitors the compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

The risk management framework aims at,

- Improve financial risk awareness and risk transparency
- Identify, control and monitor key risks
- Identify risk accumulations
- Provide management with reliable information on the Company's risk situation
- Improve financial returns

B) The company's activities expose it to market risk, liquidity risk and credit risk. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

Risk	Exposure arising from	Measurement	Management
Credit risk	Cash and cash equivalents, trade receivables, financial assets measured at amortised cost	Ageing analysis, credit ratings	Credit Limits and Letters of Credit
Liquidity risk	Borrowings and other liabilities	Rolling cash flow forecasts	Availability of committed credit lines and borrowing facilities
Market risk - Interest rate	Long term borrowings at fixed rates for one year	Sensitivity analysis	Credit rating
Market risk - Commercial	Price variations	Sensitivity analysis	Product manufacturing planning

a) Credit risk:

i) Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables), from cash and cash equivalents, deposits with banks. The management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis.

ii) Financial assets that are neither past due nor impaired

Cash and cash equivalents, deposits with banks and security deposits are neither past due nor impaired.

Cash and cash equivalents, deposits are held with banks which are reputed and credit worthy banking institutions. Hence the expected credit loss is negligible.

iii) Financial assets that are past due but not impaired

Credit risk arising from trade receivables is managed in accordance with the Company's established policy, procedures and control relating to customer credit risk management. The average credit period on sales of products is less than 45 days. All trade receivables are reviewed and assessed for default on a quarterly basis. For trade receivables, as a practical expedient, the Company computes credit loss allowance based on a provision matrix. The provision matrix is prepared based on historically observed default rates over the expected life of trade receivables and is adjusted for forward-looking estimates. The provision matrix at the end of the reporting period is as follows.



Ageing	Expected Credit Loss (%)
With in the Credit Period	0%
Up to 60 days past due	0.25%
60-90 days past due	0.5%
More than 90 days past due	1%

b) Liquidity risk:

i) Liquidity risk is defined as the risk that the Company will not be able to settle or meet its obligations on time or at a reasonable price. The Company's objective is to maintain optimum level of liquidity to meet its cash and collateral requirements at all times. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit line to meet obligations. Due to the dynamic nature of underlying business, company maintains flexibility in funding by maintaining availability under committed credit lines.

ii) Maturities of financial liabilities

The table below analyse the company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non derivative financial liabilities:
As on March 31,2026

Current maturities of financial liabilities	Less than 6 months	6 months to 12 months	Greater than 12 months	Total
Non derivatives				19,040.26
Borrowings	6,015.35	4,341.64	8,683.27	1,040.17
Trade payables	1,040.17	-	-	122.58
Other financial liabilities	122.58	-	-	

As on March 31,2025

Current maturities of financial liabilities	Less than 6 months	6 months to 12 months	Greater than 12 months	Total
Non derivatives				16,793.87
Borrowings	1,007.35	5,262.17	10,524.35	638.09
Trade payables	638.09	-	-	12.11
Other financial liabilities	12.11	-	-	

c) Market Risk

i) Interest Rate Risk -

The company's main interest rate risk arises from long term borrowings with variable rates, which expose the Company to cash flow interest rate risk.

Sensitivity to changes in interest rates

Particulars	Impact on profit	
	F.Y.2025-26	F.Y.2024-25
Sensitivity Analysis of Borrowings		
Rate of Interest Increase by 1%		
Term loans	5.29	-
Overdraft Facility	2.00	-
	7.29	-
Rate of Interest Decrease by 1%		
Term loans	-5.29	-
Overdraft Facility	-2.00	-
	(7.29)	-

ii) Commercial risk -

The commercial risk is the risk due to the change in market prices of raw materials and finished goods and it is measured through sensitivity analysis by taking variance of 5%

1. Selling price risk

Particulars	Impact on profit	
	F.Y.2025-26	F.Y.2024-25
Selling Price Increase by 5%		
Sale of Ethanol	1,054.34	-
	1,054.34	-
Selling Price Decrease by 5%		
Sale of Ethanol	-1,054.34	-
	-1,054.34	-

2. Raw materials price risk

Particulars	Impact on profit	
	F.Y.2025-26	F.Y.2024-25
Price Increase by 5%		
Inventory	222.02	(1.51)
	222.02	(1.51)
Price Decrease by 5%		
Inventory	-222.02	1.51
	-222.02	1.51

3.5 Capital management

The company's objectives when managing capital is to safeguard their ability to continue as a going concern, maintain a strong credit rating and healthy capital ratios in order to support its business and provide adequate return to shareholders through continuing growth and maximise the shareholders value. The company sets the amount of capital required on the basis of annual business and long term operating plans which include capital and other strategic investments. The funding requirements are met through a mixture of equity, internal fund generation and borrowed funds. The company tries to maintain an optimal capital structure to reduce cost of capital and monitors capital on the basis of debt-equity ratio.

Debt Equity Ratio		F.Y.2025-26	F.Y.2024-25
Particulars			
Debt		8,683.27	10,524.35
Borrowings-Non current		2,756.25	2,755.49
Current maturities of long term debt		11,439.53	13,279.84
Total Debt		2,810.00	2,810.00
Equity Share Capital		1,358.15	(24.64)
Other Equity		4,168.15	2,785.36
Total Equity		2.74	4.77
Debt to equity Ratio			

